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Abstract. Background/Aim: Cannabinoids are widely used
in the management of pain, nausea and cachexia in cancer
patients. However, there has been no objective clinical
evidence of any anticancer activity yet. The aim of this study
was to assess the effects of pharmaceutical-grade synthetic
cannabidiol on a range of cancer patients. Patients and
Methods: We analysed the data routinely collected, as part
of our treatment program, in 119 cancer patients over a four-
year period. Results: Clinical responses were seen in 92% of
the 119 cases with solid tumours including a reduction in
circulating tumour cells in many cases and in other cases, a
reduction in tumour size, as shown by repeat scans. No side-
effects of any kind were observed when using pharmaceutical
grade synthetic cannabidiol. Conclusion: Pharmaceutical-
grade synthetic cannabidiol is a candidate for treating breast
cancer and glioma patients. 
The phytocannabinoids are a group of chemicals extracted
from the cannabis plant. A number of them are able to
impede cancer cell growth, induce apoptosis and autophagy,
and inhibit angiogenesis. The most widely known
phytocannabinoid is Δ9-tetrahydrocannabinol (THC), and
although it possesses these anticancer effects, it is also
psychoactive, which has arguably hampered its clinical
development. It is thought that these actions are mediated, in
part, by binding to cannabinoid receptors that are expressed
on a number of tissue types (1). As one type of the receptor
is found exclusively on brain cells, studies using THC have
focused on this tissue type. In vitro data were promising and,
in 2016, a pilot clinical study in patients with glioblastoma
multiforme indicated THC was safe; however, no clear
activity was reported (2). The dosages were possibly on the
conservative side, to minimise psychoactivity that would
naturally restrict the use of THC as drug.
Of the 80+ phytocannabinoids, THC is possibly the only
one to exhibit this psychoactivity. More recently, studies have
diverted away from THC and focussed on other cannabinoids.
The next most abundant compound is cannabidiol (CBD),
which has a low affinity for the canonical cannabinoid
receptors. In contrast to THC, in its pure state, according to
the World Health Organisation, CBD did not have abuse
potential and caused no harm (3). Studies have shown that in
addition to being able to induce cell death directly, it is also
capable of interfering with intracellular signalling (4).
Alterations to pathways such as the PI3K/AKT/mTOR and
the ERK, suggests that CBD can modify the way certain
cancer cells react to other treatments. Indeed, studies have
shown that combining CBD with conventional chemotherapy
such as cytarabine and vincristine can lead to enhanced
anticancer activity through modifications to these signalling
pathways (5, 6). Furthermore, the sequence in which these
drugs are administered can also influence overall activity (5).
Studies have also indicated that in certain leukaemia cell
lines, CBD can increase the expression of the cyclin-
dependent kinase inhibitor p21waf1 (6). This increased level
appears to be maintained by CBD, which inadvertently
impedes cell death. Cytotoxicity can be restored in these cells
if the treatment regimen was altered to allow for a temporary
cessation of exposure to CBD. Thus, the general efficacy of
CBD may also be altered by adapting treatment protocols that
include “drug-free” phases (6).
The findings of a number of studies designed to examine
the role of cannabinoids in in the management of cancer
symptoms varied (7). The most recent prospective analysis of
nearly 3,000 patients using medical marijuana showed that a
large proportion of patients reported improvement in their
condition (8). Patients often feel that conventional therapies
are not working for them, and so they search the internet for
alternative medicines. It is here that they find stories about
cannabis working in patients with cancer, and understandably
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feel it is a route for them. The cannabis products they use vary,
and can be in the form of whole-plant extracts or purified oils;
however, whatever the source, they self-prescribe dosages. A
number of anecdotal positive responses have been reported,
which sustains the interest in this type of medication.
In order to assess its potential use, we focused on giving
patients with advanced cancer who requested CBD a
pharmaceutical-grade synthetic product at appropriate doses.
Activity of synthetic cannabinoid WIN on human cancer
cell lines has been reported (9). Every patient in this study
signed an informed consent allowing anonymous use of
their data.
Case Presentations
Patients were given synthetic, pharmaceutical-grade CBD (STI
Pharmaceuticals), registered under the Pharmaceutical Specials
scheme in oily drops at 5% (w/v) in 20 ml bottles. Each drop
contained 1 mg of synthetic CBD in neutral oil. This was
prescribed on an informed consent basis. 119 cancer patients
decided to have this treatment (Table I), and most of them had
metastatic cancers. Of the 119 patients, 28 were given CBD as
the only treatment. A third of these patients had already been
taking cannabis oil extracted from the cannabis plant that had
been bought on the Internet, with no beneficial response. This
is currently illegal, as the Medicines and Health Regulatory
Agency has defined CBD as a medicinal product, which can
only be prescribed under the Pharmaceutical Specials scheme,
as it is not currently a licensed medicinal product (10).
The majority of the patients were assessed using a
circulating tumour cell test before and after treatment (11),
since this is cheaper than carrying out repeated scans. A
number of patients however, as a matter of a normal
treatment course, had relevant scans. CBD was administered
on three days on and three days off basis, which clinically
was found to be more effective than giving it as a continuous
dose. The average dose was 10 mg twice a day. For increased
tumour mass, the dose was increased, in some cases up to 30
drops twice a day (30 mg). In a number of cases where stable
disease was present, the dose was reduced to five drops twice
a day (5 mg). In some cases, Sativex, which is licensed for
use in multiple sclerosis, was used in conjunction with CBD
as a source of THC, which synergises with CBD (12). A
fraction of the dose used for multiple sclerosis was used. Two
sprays of Sativex were given twice a day in three days on and
three days off pattern, as in the case of pharmaceutical-grade
synthetic CBD; patients on continuous dosing did not do as
well as those on this on-off repeating regimen. Some of our
patients reverted to cannabis oil bought on the Internet, and
following this, 80% of these cases relapsed.
We were unable to define a maximum tolerated dose for
CBD, as there was a complete absence of side effects. The
minimum duration of treatment required for CBD was six
months, but many continued for longer. Less than six months
appeared inadequate and had little effect, and therefore cases
in which CBD was used for less than six months have been
defined as un-assessable, and not included in the current
cohort of 119 cases.
We sought clear objective evidence of potential efficacy
where no other treatment option was available. The most
impressive case was a five-year-old male patient with an
anaplastic ependymoma, a very rare brain tumour. The
patient had had all standard treatments, surgery on two
occasions followed by chemotherapy and conformal photon
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Table I. Tabular presentation of our results on 119 cancer patients.
Cancer                                    Tumour       Stable      Extended median        Slowed        No effect/         Died      CBD as only      Unknown     Total 
type                                             free          disease              survival             progression         result                              treatment           outcome       cases
Anaplastic ependymoma                                                           3                                                                                           3                                          3
DIPG                                                                                           1                                                                                           1                                          1
Glioblastoma multiforme                                                           4                           3                                          3                  4                                          7
Bladder                                                             1                        1                                                                                                                                       2
Breast                                            7                21                        8                                                  3                   6                  6                                        39
Head and Neck                             1                                                                         1                                                                                                           2
Prostate                                                           10                        3                                                                       3                  6                                        16
Neuroendocrine                                                1                                                                                                                                                                 1
Non-Hodgkin's lymphoma          1                  6                                                                                                 1                  3                                          8
Non-small cell lung                                                                  2                                                                       2                  2                                          2
Colorectal                                     1                                            9                           2                     1                   6                                                            13
Pancreatic                                                                                   2                                                                       2                  2                                          4
Ovarian                                                                                       5                           1                                          3                  1                                          6
Miscellaneous                              2                  6                        5                           1                     1                   1                                            1              15
Total                                            12                45                      43                           8                     5                 27                28                        1             119
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Figure 1. Patient with ependymoma. A) A scan on the 6th of Jan 2016 showed enlargement of the posterior fossa mass. There were some, particularly
multimodal features of radionecrosis, but in the context of a previously rapidly progressive tumour, an element of disease progression was also
being considered. B) A subsequent scan on the 13th April 2016 showed further tumour progression and development of moderately severe
supratentorial hydrocephalus. C) On the 30 Sept 2016, scans showed substantial improvement/reduction in size of the residual disease. There had
been a substantial improvement in appearances, with marked reduction in size of the posterior fossa tumour from 3.4×3.2 cm in the sagittal plane
to 1.7×1.7 cm. D) Scans performed on the 14th Dec 2016, showed a slow improvement; with impressive resolution of left CPA recurrent ependymoma. 
Figure 2. Patient with tanycytic ependymoma. A) A scan on the 13th Jan 2017 showed a reduction in the size and enhancement of the left periventricular
tumour. There was almost complete resolution of the parenchymal enhancement with a couple of small ependymal nodules remaining, but slightly
smaller. There was no significant change in the T2/FLAIR appearance with Wallarian degeneration extending into the corticospinal tracts. B) A follow-
up scan performed on the 21 Feb 2018 revealed evidence of disease progression with a near doubling of the enhancing soft tissue arising from the
ependymal surface of the left lateral ventricle and projecting into the body of the left lateral ventricle. There are new enhancing foci in the left putamen
and subthalamic region with further non-enhancing T2 hyperintense tumour expanding inferiorly into the left cerebral peduncle.
radiotherapy. No further treatment options were available to
him when treatment on CBD started in February 2016. A
scan carried out in December 2016 showed that tumour
volume had decreased by ~60%. Further scans, carried out
since December 2016, continued to show stable disease.
CBD was the only treatment. Four scans with the scan report
at the top of each scan are appended (Figure 1A-D).
Another impressive case was a 50-year-old patient with
progressive tanycytic ependymoma Grade 2 diagnosed in
June 2013, treated with biopsy and radical radiotherapy,
which was completed on 3rd June 2015. He refused
chemotherapy, and had no further treatment options. He
started on pharmaceutical-grade synthetic CBD in July 2016
at a dose of 10 drops twice a day, three days on and three
days off (10 mg). Prior to this he had been taking, for some
time, metformin, mebendazole, doxycycline and atorvastatin
from an oncology clinic in Central London.
In January 2017 a repeat scan showed tumour reduction. At
that point the patient stopped taking pharmaceutical-grade
synthetic CBD and switched to cannabis oil extract obtained
from an internet website. Further scans carried out in February
2018 showed doubling of tumour size and more growth down
the brain stem. He has  since restarted pharmaceutical-grade
synthetic CBD and throughout continued to take the
metformin, atorvastatin, doxycycline and mebendazole. So, the
only change in November 2017 had been stopping the
pharmaceutical-grade synthetic CBD and switching to cannabis
oil extract obtained on the Internet (Figure 2A and B).
Other patients who clearly improved using pharmaceutical-
grade synthetic CBD had prostate cancer, breast cancer,
oesophageal cancer and a lymphoma, and these are
summarised in Table II.
Discussion
From our laboratory studies, we would not expect any
significant anti-cancer activity using continuous CBD alone,
as we have only observed cancer cell line apoptosis (cell
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Table II. Examples of patients who have been using pharmaceutical-grade synthetic CBD.
Age/Gender                    Diagnosis                                                                                               Comments
72/male                       Prostate cancer                 Patient has had cancer immunotherapy, sono and photodynamic therapy (14) which was successful. 
                                                                                   On resumption of testosterone injections his prostate specific antigen (PSA) levels increased
                                                                                       to 16. We started him on CBD early in 2015 at a dose of 10 drops twice a day (10 mg), 
                                                                                three days on and three days off. There was a reduction in circulating tumour cells (CTCs) with 
                                                                                   CBD alone from an initial 8.1 cells/7.5 ml to 5.9 cells/7.5 ml, then steady reduction over the 
                                                                                             course of 12 months of 4.8, 4.2 then 3.2 cells/7.5 ml. He is still under treatment.
68/female                Breast cancer with                                           Patient was diagnosed in March 2014 with progressive disease. 
                                  bone metastases                           She started local radiotherapy. We started her on CBD in January 2015, all subsequent 
                                                                                 scans showed stable disease. She has had no treatment other than CBD following radiotherapy.
65/female                Oesophageal cancer                   Patient was diagnosed in May 2016. She had a stent put on place at that time and was given 
                                                                                          an expected survival of three months. Since then, she has been on CBD as the only 
                                                                                         treatment, and she has continued to refuse all standard treatments and investigations. 
                                                                                                       We last saw her in November 2016, when she was looking well and 
                                                                                                                  had in fact regained weight. She died in January 2018.
65/female                     Breast cancer                                 Patient was diagnosed in November 2009, and refused all conventional treatments 
                                                                                  and investigations. On examination she had a large fungating lesion 15 cm in diameter in the 
                                                                                             left breast, and also palpable left axillary nodes. She began treatment with CBD 
                                                                                                in October 2014. We persuaded her to have radiotherapy in November 2014. 
                                                                                          She only agreed to have half the recommended treatment course. She has continued 
                                                                                                          on CBD alone and on her last appointment the tumour in her left 
                                                                                                             breast was 2 cm in diameter, with no palpable axillary nodes.
62/female                     Breast cancer                                               We first saw this patient in May 2014 and she has been on CBD, 
                                                                                                as the only treatment, since October 2014. We carried out various CTC tests 
                                                                                           in October 2014 which showed 10.6 cells per 7.5 ml. Subsequent tests in July and
                                                                                           October 2015, November 2016 and October 2017 showed CTCs to be 7.3, 6.8, 5.0 
                                                                                              and 3.9 cells/7.5 ml, respectively. Patient is currently stable with no symptoms.
67/female                    Lobular breast                                     Patient was diagnosed in November 2012. We first saw her in March 2014, 
                                          cancer                               we gave her CBD in October 2014, which is the only method of treatment. Initial CTCs in 
                                                                               October 2014 was 9.3 cells per 7.5ml. Follow-up measurements in September 2015, March 2016 
                                                                                           and March 2017 have been 7.5, 6.8 and 3.0 cells/7.5 ml, respectively. All standard 
                                                                                             clinical investigations and scans have been normal since the beginning of 2015.
death) when the agent is washed out of culture and
withdrawn (13). We have also observed a potential increased
cell killing ability when given after chemotherapy.
Cannabinoids have an accepted useful role in the
management of cancer symptoms, namely pain control,
nausea and cachexia, but not as part of primary treatment.
The fact that we have been able to document improvement
in cancer in few patients strongly supports further studies of
CBD-based products in cancer patients who have exhausted
standard treatments. Our primary data in a murine glioma
model (14) showing enhanced sensitivity to radiotherapy
without any side-effects, suggests this would be an ideal
clinical trial to initiate in the first instance.
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